# Heart prevention recommendations by age Guide · id `cardio:guide-prevention-recommendations` · Cardiovascular Atlas · release `f4600233112e1c27` (public) > General information only. This guide shows what the sources it cites say. It is not medical advice, it cannot tell you what is right for you, and no clinician has reviewed it. Talk to a qualified health professional about your own care. In an emergency, call your local emergency number. > General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations. Which USPSTF recommendations exist on blood pressure screening, statins and aspirin, which ages and risk groups each one names, and questions to ask a clinician. ## About the USPSTF - The U.S. Preventive Services Task Force (USPSTF) is a volunteer panel of experts that makes recommendations on preventive services. [1, 2] - The USPSTF says its advice is meant only for people without symptoms or other signs of the condition in question. [3] - The USPSTF says clinical decisions involve more than the evidence, and clinicians should adapt them to each patient. [4, 5] ## How the USPSTF grades a recommendation - Each USPSTF recommendation receives a letter grade from A to D, or an I statement. [6, 7] - A grade reflects how strong the evidence is and how benefits compare with harms, and the USPSTF says it does not weigh cost. [8, 9] - Grade A means the USPSTF recommends a service and has high certainty that its overall benefit is substantial. [10] - Grade B means a recommendation with high certainty of a moderate benefit, or moderate certainty of a moderate to substantial one. [11, 12] - Grade C means the USPSTF recommends offering a service selectively, guided by clinician judgment and patient wishes, and is at least moderately certain that the overall benefit is small. [13, 14] - Grade D means the USPSTF recommends against a service, being moderately or highly certain that it gives no benefit overall or does more harm than good. [15, 16] - An I statement means the USPSTF could not tell whether a service does more good than harm, because the evidence is lacking, of low quality or conflicting. [17, 18] ## Where the age ranges start and end - The blood pressure screening recommendation starts at age 18, and the statin and aspirin recommendations start at age 40 for adults with no cardiovascular disease. [19, 20, 21] - For adults with no cardiovascular disease, the USPSTF recommends against starting aspirin as prevention from age 60, and from age 76 it finds the evidence too limited on starting a statin. [22, 23] ## Blood pressure screening - The USPSTF’s 2021 statement on blood pressure screening covers adults aged 18 or older with no known high blood pressure. [19, 24, 25] - It is a grade A recommendation, reaffirmed from 2015, with high certainty of a substantial net benefit. [19] - It recommends screening with a blood pressure reading taken in the office, then readings outside the clinic to confirm a diagnosis before treatment. [19] - The USPSTF page says evidence on the best screening interval is limited, so it lists reasonable options. [26] - One option is yearly screening from age 40, and from age 18 for adults who face higher risk. [27] - Its examples of higher risk include Black adults, adults whose blood pressure is high-normal, and adults who are overweight or have obesity. [28] - Another option, as appropriate, is screening every three to five years for adults between 18 and 39 who are not at higher risk and had a normal reading before. [29, 30] ## Statins - The USPSTF’s 2022 statin statement covers adults aged 40 or older with no cardiovascular disease and no sign or symptom of it. [20, 31, 32] - For adults between 40 and 75 who have at least one risk factor and whose estimated 10-year risk is 10% or more, it advises prescribing a statin (grade B). [31] - The risk factors it names are abnormal blood fats, diabetes, high blood pressure and smoking. [31] - It judges the net benefit in this group to be at least moderate, with moderate certainty. [31] - For adults between 40 and 75 who have at least one of these risk factors and whose estimated 10-year risk is 7.5% to under 10%, the USPSTF advises offering a statin selectively (grade C), with a smaller likelihood of benefit. [33] - From age 76, the USPSTF finds the evidence too limited to judge whether starting a statin does more good than harm (an I statement). [23] - In reply to comments, the USPSTF repeated that its statement is about starting a statin, when asked about adults aged 76 or older who already take one. [34, 35] - The USPSTF says the statin statement leaves out adults whose LDL cholesterol is above 190 mg/dL and adults with known familial hypercholesterolemia. [36] - The page describes these adults as being at very high risk and points to other organizations’ guidelines for them. [37, 38] ## The 10-year risk estimate - The statin and aspirin groups depend partly on an estimated chance of a cardiovascular event over 10 years. [39] - The cut-offs are 10% and 7.5% for statins and 10% for aspirin. [39] - For clinicians, the USPSTF pages list estimating this risk with a risk estimator as a step in using these recommendations. [40, 41] ## Aspirin - The USPSTF’s 2022 aspirin statement covers adults aged 40 or older with no cardiovascular disease, no sign or symptom of it and no raised risk of bleeding. [21, 42, 43, 44] - The USPSTF’s examples of raised bleeding risk include recent bleeding, past digestive tract ulcers, other medical conditions and medicines that increase bleeding risk. [45, 46] - For adults between 40 and 59 whose risk over 10 years is estimated at 10% or more, the USPSTF says starting low-dose aspirin as prevention should be decided case by case (grade C). [42] - It calls the net benefit small, with moderate certainty. [42] - It says people who are not at raised bleeding risk and are prepared to take a low dose every day have a better chance of benefit. [42] - For adults 60 or older with no cardiovascular disease, the USPSTF recommends against starting low-dose aspirin as prevention (grade D). [22] - It reports moderate certainty that starting aspirin at this age has no net benefit. [22] - The page says aspirin lowers the chance of cardiovascular events but raises the chance of bleeding in the digestive tract, bleeding inside the skull and stroke caused by bleeding. [47] - The USPSTF words its aspirin and statin recommendations as being about starting the medicine. [48, 49, 50] ## Guidance from other groups - A 2026 guideline from the American College of Cardiology, the American Heart Association and other societies replaces the 2018 guideline on managing blood cholesterol. [51] ## Questions to ask 1. Which of the screening options on the USPSTF page fits my age and risk, and how often will my blood pressure be checked? 2. Do I have any of the risk factors the statin recommendation names, and what is my estimated chance of a cardiovascular event over 10 years? 3. Which risk estimator is used to work out a 10-year risk, and which events does it count? 4. Do these recommendations apply to me if I have heart disease, very high LDL cholesterol or familial hypercholesterolemia? 5. If I am 76 or older, what does it mean that the USPSTF finds the evidence too limited on starting a statin? 6. Am I at raised risk of bleeding, and how does that affect whether aspirin is an option for me? 7. If I already take a statin or aspirin, do these recommendations about starting apply to me? 8. How do the USPSTF recommendations fit with other groups’ guidance on cholesterol? ## Sources 1. About the USPSTF (U.S. Preventive Services Task Force) (Webpage, U.S. Preventive Services Task Force) . Locator: Who We Are, sentence 1. Retrieved 2026-10-14. 2. About the USPSTF (U.S. Preventive Services Task Force) (Webpage, U.S. Preventive Services Task Force) . Locator: Who We Are, sentence 2, first part. Retrieved 2026-10-14. 3. About the USPSTF (U.S. Preventive Services Task Force) (Webpage, U.S. Preventive Services Task Force) . Locator: What We Do, sentence 3, first part. Retrieved 2026-10-14. 4. Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, closing paragraph, sentence 1. Retrieved 2026-10-15. 5. Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, closing paragraph, sentence 2. Retrieved 2026-10-15. 6. About the USPSTF (U.S. Preventive Services Task Force) (Webpage, U.S. Preventive Services Task Force) . Locator: What We Do, sentence 1, first part. Retrieved 2026-10-14. 7. Grade Definitions (U.S. Preventive Services Task Force) (Webpage, U.S. Preventive Services Task Force) . Locator: Page introduction, sentence 1 (part). Retrieved 2026-10-15. 8. About the USPSTF (U.S. Preventive Services Task Force) (Webpage, U.S. Preventive Services Task Force) . Locator: What We Do, sentence 1, last part. Retrieved 2026-10-14. 9. About the USPSTF (U.S. Preventive Services Task Force) (Webpage, U.S. Preventive Services Task Force) . Locator: What We Do, sentence 2. Retrieved 2026-10-14. 10. Grade Definitions (U.S. Preventive Services Task Force) (Webpage, U.S. Preventive Services Task Force) . Locator: Grade table for votes after July 2012, grade A. Retrieved 2026-10-15. 11. Grade Definitions (U.S. Preventive Services Task Force) (Webpage, U.S. Preventive Services Task Force) . Locator: Grade table for votes after July 2012, grade B, part 1 of 2. Retrieved 2026-10-15. 12. Grade Definitions (U.S. Preventive Services Task Force) (Webpage, U.S. Preventive Services Task Force) . Locator: Grade table for votes after July 2012, grade B, part 2 of 2. Retrieved 2026-10-15. 13. Grade Definitions (U.S. Preventive Services Task Force) (Webpage, U.S. Preventive Services Task Force) . Locator: Grade table for votes after July 2012, grade C, part 1 of 2. Retrieved 2026-10-15. 14. Grade Definitions (U.S. Preventive Services Task Force) (Webpage, U.S. Preventive Services Task Force) . Locator: Grade table for votes after July 2012, grade C, part 2 of 2. Retrieved 2026-10-15. 15. Grade Definitions (U.S. Preventive Services Task Force) (Webpage, U.S. Preventive Services Task Force) . Locator: Grade table for votes after July 2012, grade D, part 1 of 2. Retrieved 2026-10-15. 16. Grade Definitions (U.S. Preventive Services Task Force) (Webpage, U.S. Preventive Services Task Force) . Locator: Grade table for votes after July 2012, grade D, part 2 of 2. Retrieved 2026-10-15. 17. Grade Definitions (U.S. Preventive Services Task Force) (Webpage, U.S. Preventive Services Task Force) . Locator: Grade table for votes after July 2012, I statement, part 1 of 2. Retrieved 2026-10-15. 18. Grade Definitions (U.S. Preventive Services Task Force) (Webpage, U.S. Preventive Services Task Force) . Locator: Grade table for votes after July 2012, I statement, part 2 of 2. Retrieved 2026-10-15. 19. Claim `cardio:claim-uspstf-2021-hypertension-screening-a`: The USPSTF advises screening adults aged 18 or older for hypertension with an office blood pressure reading, and advises taking measurements outside the clinical setting to confirm the diagnosis before treatment starts (grade A). It reaffirmed its 2015 recommendation and, using a reaffirmation process, concluded with high certainty that screening has a substantial net benefit. - Applies to: People from age 18 with no known hypertension, as the abstract defines the population.; Not stated in the abstract. The recommendation concerns screening with a reading taken in the office and confirmation with readings taken outside the clinical setting.; United States (a USPSTF recommendation; the abstract gives US figures); Adults aged 18 or older. Follow-up: Not applicable (guideline context) - Limitations: A reaffirmation of the 2015 recommendation, reached through what the abstract calls a reaffirmation deliberation process. The abstract names no screening interval and no method for out-of-office measurement; those details were not read. The A label is read from the parenthesis that follows the last recommendation sentence in the abstract. The Task Force certainty is its own rating, not GRADE. Only the PubMed abstract and the date line of the USPSTF page were read. No recommendation record is written, because this atlas has no record for blood pressure screening itself. - Supports: Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 1. Retrieved 2026-10-15. - Supports: Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 2. Retrieved 2026-10-15. - Supports: Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 3. Retrieved 2026-10-15. - Supports: Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement (Guideline, JAMA) . Locator: Abstract, EVIDENCE ASSESSMENT, sentence 1. Retrieved 2026-10-15. - Supports: Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement (Guideline, JAMA) . Locator: Abstract, OBJECTIVE, sentence 1, fragment 1 of 3. Retrieved 2026-10-15. - Background: Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement (Guideline, JAMA) . Locator: Page header, date line of the final recommendation statement. Retrieved 2026-10-15. 20. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, who it applies to, sentence 1. Retrieved 2026-10-15. 21. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, who it applies to, part 1 of 4. Retrieved 2026-10-15. 22. Claim `cardio:claim-uspstf-2022-aspirin-60-plus-d`: The USPSTF recommends against starting low-dose aspirin as primary prevention of cardiovascular disease for adults aged 60 or older (grade D). The abstract says it found, with moderate certainty, no net benefit from starting aspirin at that age. - Applies to: Adults aged 60 or older with no known cardiovascular disease (including no past heart attack or stroke), no signs or symptoms of it, and no raised bleeding risk. The abstract gives examples of raised bleeding risk, among them stomach ulcers, recent bleeding, other conditions and medicines that increase bleeding.; Not stated in the abstract. The statement is addressed to clinicians.; United States (a USPSTF recommendation; the abstract gives US disease figures); Adults aged 60 or older. Follow-up: Not applicable (guideline context) - Limitations: Applies to starting aspirin in people without known cardiovascular disease, not to people already taking it and not to people with a heart attack or stroke. The D label is read from the parenthesis that follows the recommendation sentence in the abstract. The Task Force certainty is its own rating, not GRADE. Only the PubMed abstract and the date line of the USPSTF page were read. - Supports: Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 4. Retrieved 2026-10-15. - Supports: Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 5. Retrieved 2026-10-15. - Supports: Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, EVIDENCE ASSESSMENT, sentence 2, fragment 1 of 2. Retrieved 2026-10-15. - Supports: Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, EVIDENCE ASSESSMENT, sentence 2, fragment 2 of 2. Retrieved 2026-10-15. - Background: Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Page header, date line of the final recommendation statement. Retrieved 2026-10-15. 23. Claim `cardio:claim-uspstf-2022-statin-76-plus-i`: For adults aged 76 or older, the USPSTF finds the evidence now available too limited to judge whether starting a statin for primary prevention of cardiovascular events and death does more good than harm (an I statement). - Applies to: Adults aged 76 or older with no known cardiovascular disease and no signs or symptoms of it, who are considering starting a statin for primary prevention.; Not stated in the abstract. The statement is addressed to clinicians who prescribe statins.; United States (a USPSTF recommendation; the abstract gives US disease figures); Adults aged 76 or older. Follow-up: Not applicable (guideline context) - Limitations: An I statement means the evidence is too thin to support a recommendation either way. It is not advice against a statin, and it says nothing about people already taking one. Only the PubMed abstract was read. - Supports: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 4, fragment 1 of 2. Retrieved 2026-10-15. - Supports: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 4, fragment 2 of 2. Retrieved 2026-10-15. - Supports: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 5. Retrieved 2026-10-15. 24. Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Recommendation Summary, population. Retrieved 2026-10-15. 25. Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Page header, date line. Retrieved 2026-10-15. 26. Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, screening interval, lead-in. Retrieved 2026-10-15. 27. Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, screening interval, first option, part 1 of 2. Retrieved 2026-10-15. 28. Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, screening interval, first option, part 2 of 2. Retrieved 2026-10-15. 29. Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, screening interval, second option, part 1 of 2. Retrieved 2026-10-15. 30. Screening for Hypertension in Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, screening interval, second option, part 2 of 2. Retrieved 2026-10-15. 31. Claim `cardio:claim-uspstf-2022-statin-b`: The USPSTF advises clinicians to prescribe a statin as primary prevention of cardiovascular disease to adults between 40 and 75 who have at least one cardiovascular risk factor (abnormal blood fats, diabetes, high blood pressure or smoking) and whose estimated chance of a cardiovascular event within 10 years is 10% or more. It grades this recommendation B. The abstract says the Task Force found a net benefit of at least moderate size, with moderate certainty. - Applies to: Adults aged between 40 and 75 with no known cardiovascular disease and no signs or symptoms of it, who have at least one cardiovascular risk factor (abnormal blood fats, diabetes, hypertension or smoking) and whose estimated chance of a cardiovascular event within ten years is 10% or more.; Not stated in the abstract. The statement is addressed to clinicians who prescribe statins.; United States (a USPSTF recommendation; the abstract gives US disease figures); Adults aged 40 to 75. Follow-up: Not applicable (guideline context) - Limitations: Primary prevention only: adults with no history of cardiovascular disease and no signs or symptoms of it. The Task Force states its own certainty level, which is not a GRADE rating, so the claim certainty stays not assessed. The advice depends on an estimated risk; the abstract does not say which risk equation to use. The B label is read from the parenthesis that follows the first recommendation sentence in the abstract. Only the PubMed abstract and the date line of the USPSTF page were read, not the full statement or its evidence review. PubMed lists no correction to the statement (checked 2026-10-15). - Supports: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 1. Retrieved 2026-10-15. - Supports: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, start of sentence 2 (the grade label that follows sentence 1). Retrieved 2026-10-15. - Supports: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, EVIDENCE ASSESSMENT, sentence 1. Retrieved 2026-10-15. - Background: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, POPULATION, sentence 1. Retrieved 2026-10-15. - Background: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Page header, date line of the final recommendation statement. Retrieved 2026-10-15. 32. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Page header, date line. Retrieved 2026-10-15. 33. Claim `cardio:claim-uspstf-2022-statin-c`: For the same group of adults between 40 and 75 with at least one cardiovascular risk factor, when the estimated 10-year chance of a cardiovascular event is 7.5% to under 10%, the USPSTF advises clinicians to offer a statin selectively for primary prevention. It grades this recommendation C and says benefit is less likely than in the group at 10% or more. The abstract says the Task Force found a net benefit that is at least small, with moderate certainty. - Applies to: Adults aged between 40 and 75 with no known cardiovascular disease and no signs or symptoms of it, who have at least one cardiovascular risk factor and whose estimated chance of a cardiovascular event within ten years is 7.5% to under 10%.; Not stated in the abstract. The statement is addressed to clinicians who prescribe statins.; United States (a USPSTF recommendation; the abstract gives US disease figures); Adults aged 40 to 75. Follow-up: Not applicable (guideline context) - Limitations: A C grade means a selective offer to individual patients, not a general recommendation, so this atlas keeps it as a claim and writes no recommendation record for it (the direction field has no value for selective offering). The C label is read from the parenthesis that follows this statement in the abstract. The Task Force certainty is its own rating, not GRADE. Only the PubMed abstract was read. - Supports: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 2, fragment 1 (without the grade label). Retrieved 2026-10-15. - Supports: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 2, fragment 2 of 2. Retrieved 2026-10-15. - Supports: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 3. Retrieved 2026-10-15. - Supports: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, start of sentence 4 (the grade label that follows sentence 3). Retrieved 2026-10-15. - Supports: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, EVIDENCE ASSESSMENT, sentence 2, fragment 3 of 3. Retrieved 2026-10-15. 34. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Response to Public Comment, sentence 6 (part). Retrieved 2026-10-15. 35. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Response to Public Comment, sentence 5. Retrieved 2026-10-15. 36. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, who it applies to, sentence 2. Retrieved 2026-10-15. 37. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, who it applies to, sentence 3, part 1 of 2. Retrieved 2026-10-15. 38. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, who it applies to, sentence 3, part 2 of 2. Retrieved 2026-10-15. 39. Claim `cardio:claim-estimated-10-year-cvd-risk-use`: The USPSTF statin recommendation sets its risk bands on an estimated 10-year cardiovascular event risk: 10% or more for the B grade and 7.5% to under 10% for the C grade. Its aspirin recommendation uses a 10-year cardiovascular risk of 10% or more for people aged 40 to 59. The American Heart Association PREVENT equations are described in a 2024 paper as risk equations for cardiovascular disease, meaning atherosclerotic cardiovascular disease and heart failure, in US adults aged 30 to 79 without known cardiovascular disease. Their abstract does not say over what period they predict. - Applies to: Adults without known cardiovascular disease. The USPSTF statin statement applies to ages 40 to 75 and the aspirin statement to adults 40 to 59 for the risk-based grades; the PREVENT equations were developed for US adults aged 30 to 79.; Not stated in the abstracts read.; United States (USPSTF statements and the AHA PREVENT paper; the abstracts give US figures); Adults, with the age ranges above. Follow-up: Not applicable (guideline context) - Limitations: The USPSTF abstracts do not name the risk equation behind their 10-year estimates, so this claim does not say that any guideline uses PREVENT. The tools count different events: the USPSTF aspirin abstract counts heart attack and stroke, while PREVENT counts atherosclerotic cardiovascular disease and heart failure. PubMed lists two corrections to the PREVENT paper (2024-03-12 and 2026-10-14); their text was not read, so it is not known whether they change anything stated here. Only abstracts were read. - Supports: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 1 and sentence 2. Retrieved 2026-10-15. - Supports: Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 1. Retrieved 2026-10-15. - Background: Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, OBJECTIVE, sentence 1, fragment 2 of 3. Retrieved 2026-10-15. - Supports: Development and Validation of the American Heart Association's PREVENT Equations (Publication, Circulation) . Locator: Abstract, BACKGROUND, sentence 1. Retrieved 2026-10-15. Source state: Corrected. - Supports: Development and Validation of the American Heart Association's PREVENT Equations (Publication, Circulation) . Locator: Abstract, BACKGROUND, sentence 3. Retrieved 2026-10-15. Source state: Corrected. - Supports: Development and Validation of the American Heart Association's PREVENT Equations (Publication, Circulation) . Locator: Abstract, METHODS, sentence 2. Retrieved 2026-10-15. Source state: Corrected. 40. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, putting it into practice, step 2. Retrieved 2026-10-15. 41. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, putting it into practice, adults 40 to 59 step. Retrieved 2026-10-15. 42. Claim `cardio:claim-uspstf-2022-aspirin-40-59-c`: The USPSTF says that for people aged between 40 and 59 whose 10-year cardiovascular risk is 10% or more, the choice to start low-dose aspirin as primary prevention of cardiovascular disease should be made person by person (grade C). It says the net benefit in this group is small, and that people who are not at increased bleeding risk and who are prepared to take a low dose of aspirin every day stand a better chance of benefit. - Applies to: Adults aged between 40 and 59 with no known cardiovascular disease (including no past heart attack or stroke), no signs or symptoms of it, and no raised bleeding risk. The abstract gives examples of raised bleeding risk, among them stomach ulcers, recent bleeding, other conditions and medicines that increase bleeding. Their estimated 10-year cardiovascular risk is 10% or more.; Not stated in the abstract. The statement is addressed to clinicians.; United States (a USPSTF recommendation; the abstract gives US disease figures); Adults aged 40 to 59. Follow-up: Not applicable (guideline context) - Limitations: Applies to starting aspirin, not to people already taking it, and to people without known cardiovascular disease. A C grade is an individual decision, so this atlas keeps it as a claim and writes no recommendation record for it. The C label is read from the parenthesis that follows the third recommendation sentence in the abstract. The Task Force certainty is its own rating, not GRADE. Only the PubMed abstract was read. - Supports: Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 1, fragment 1 of 2. Retrieved 2026-10-15. - Supports: Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 1, fragment 2 of 2. Retrieved 2026-10-15. - Supports: Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 2. Retrieved 2026-10-15. - Supports: Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, sentence 3. Retrieved 2026-10-15. - Supports: Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, RECOMMENDATION, start of sentence 4 (the grade label that follows sentence 3). Retrieved 2026-10-15. - Background: Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: Abstract, EVIDENCE ASSESSMENT, sentence 1, fragment 2 of 2. Retrieved 2026-10-15. 43. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, who it applies to, part 2 of 4. Retrieved 2026-10-15. 44. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Page header, date line. Retrieved 2026-10-15. 45. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, who it applies to, part 3 of 4. Retrieved 2026-10-15. 46. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, who it applies to, part 4 of 4. Retrieved 2026-10-15. 47. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, additional information, bullet 3. Retrieved 2026-10-15. 48. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, the recommendation, adults 40 to 59 group. Retrieved 2026-10-15. 49. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, the recommendation, adults 60 or older group. Retrieved 2026-10-15. 50. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement (Guideline, JAMA) . Locator: USPSTF web page, Clinician Summary, the recommendation, first group. Retrieved 2026-10-15. 51. Claim `cardio:claim-acc-aha-2026-dyslipidemia-replaces-2018`: The abstract of the 2026 ACC/AHA multisociety dyslipidemia guideline says it retires and replaces the 2018 guideline on managing blood cholesterol. It says the guideline addresses evaluation, management and monitoring of people with high blood cholesterol, high triglycerides and elevated lipoprotein(a). - Applies to: Individuals with dyslipidemias, which the abstract lists as high blood cholesterol, high triglycerides and elevated lipoprotein(a). The abstract gives no age limits and no inclusion or exclusion criteria.; Not stated in the abstract. The abstract says the guideline covers evaluation, management and monitoring.; Not stated in the abstract (issued by American societies; jurisdiction not verified); Not stated in the abstract. Follow-up: Not applicable (guideline context) - Limitations: Only the abstract and the bibliographic record were read, so no threshold, target, medicine or class of recommendation from the guideline is recorded. PubMed lists two corrections to the guideline (2026-06-23 and 2026-09-08); their text was not read, so it is not known whether they change anything the abstract says. This claim states the replacement. It does not link to a record of the 2018 guideline. - Supports: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines (Guideline, Circulation) . Locator: Abstract, AIM. Retrieved 2026-10-15. Source state: Corrected. - Supports: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines (Guideline, Circulation) . Locator: Abstract, STRUCTURE, sentence 1. Retrieved 2026-10-15. Source state: Corrected. - Background: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines (Guideline, Circulation) . Locator: CommentsCorrectionsList, two ErratumIn entries. Retrieved 2026-10-15. Source state: Corrected. ## About this guide - Written for: Adults, and the people who care for them - What it covers: Covers three USPSTF recommendations only, not every USPSTF or other group’s prevention advice. Written from USPSTF pages and abstracts. It describes what the sources say and gives no advice for one person. - Pages it explains: USPSTF 2021: screening for hypertension in adults (`cardio:guideline-uspstf-2021-hypertension-screening`); USPSTF 2022: statin use for primary prevention of CVD in adults (`cardio:guideline-uspstf-2022-statin`); USPSTF 2022: aspirin use to prevent CVD (`cardio:guideline-uspstf-2022-aspirin`); Estimated 10-year cardiovascular risk (`cardio:estimated-10-year-cvd-risk`); Preventing heart attack, stroke and heart failure (`cardio:cardiovascular-prevention`) - Sources checked: 2026-10-15 - Next check due: 2027-04-15 - Estimated reading grade: 9.8 (target 10) Every sentence cites a source. Words in quotation marks are the source's own; the rest is the atlas's summary. ## Provenance Content hash: 4ce62ceeb284663dc08e9f59c8783bd50a39f38032d0e5024d1a9eebb4406735 Last substantive edit: 2026-10-15 Evidence last checked: 2026-10-15